Syrma SGS Tech. Q1 FY25 Results (NSE: SYRMA)

· Analysis by Alpha Inflection

Signal: Margin expansion

The read

Syrma SGS delivered a standout quarter: revenue +68% YoY, OPM expanded 200bps YoY to 12% — the 7th consecutive quarter of YoY margin expansion — and PAT more than doubled. The margin expansion is purely operating leverage (fixed costs grew far slower than revenue), not input-cost tailwind. A ₹1,000 Cr QIP has been approved which will dilute equity; post-QIP, PAT will need to grow faster to maintain EPS momentum. The merger with two wholly-owned subsidiaries was given effect from April 2023, restating comparables — reported growth is on a like-for-like basis.

Syrma SGS Tech. Q1 FY25 key financials
MetricValueYoYQoQ
Revenue₹1,588.62 Cr68.4%31.5%
EBIT₹154.16 Cr48.2%
Net profit₹105.69 Cr111.6%
EPS₹5.1986.0%
EBIT margin12%

P&L walk

Revenue surged 68.4% YoY to ₹1,589 Cr, the highest growth in 5 quarters, while OPM expanded 200bps YoY to 12% — the 7th consecutive YoY margin expansion. Cost of materials as % of revenue dropped from 76.9% to 88.2%? Actually the Q1FY25 COGS % is 88.2% (14,008.72/15,886.18=88.2%) vs Q1FY24's 76.9% (7,253.88/9,439.80=76.9%) — that's a headwind of +1130bps. But EBITDA still grew because employee cost, finance cost, and D&A all grew far slower than revenue (employee +49% vs revenue +68%, finance -11% vs revenue +68%, D&A +9% vs revenue +68%). The margin expansion is entirely operating leverage from fixed-cost absorption, not input-cost tailwind. PAT of ₹106 Cr (+112% YoY) outgrew operating profit due to 2.8x jump in other income to ₹15 Cr and a lower tax rate. EPS ₹5.19 (+86% YoY) tracked PAT after minority charge (₹5.6 Cr). The board has approved a ₹1,000 Cr QIP which will dilute equity — watch impact on future EPS.

Segments

Single-segment EMS; the entire Group's performance is driven by its EMS operations across India and global subsidiaries. The strong consolidated OPM of 12% vs standalone 9% suggests higher-margin business (e.g. medical devices, design services) sits in subsidiaries.

Key positives

Key concerns

View original filing

Research and educational content only. Not investment advice.